Welcome to our dedicated page for PARKERVISION SEC filings (Ticker: PRKR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on PARKERVISION's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into PARKERVISION's regulatory disclosures and financial reporting.
ParkerVision, Inc. has a prospectus supplement allowing the selling shareholders to resell up to 16,638,353 shares of common stock issuable upon conversion and interest payments on certain 2022 convertible notes with a fixed conversion price of $0.13 per share. The supplement incorporates a new Form 8-K that reports a separate capital raise completed on November 24, 2025.
In that transaction, the company sold 16,481,579 shares of common stock to accredited investors for an aggregate purchase price of $3,461,132, using its effective shelf registration statement on Form S-3. No underwriters, placement agents, brokers, or finders were involved, so no commissions or fees were paid. A subscription agreement and a press release describing the closing are filed as exhibits.
ParkerVision, Inc. is registering for resale up to 1,578,946 shares of common stock under a prospectus supplement that also incorporates a recent equity financing update. The registered amount includes 1,052,631 outstanding shares of common stock and 526,315 shares issuable upon exercise of warrants issued under a December 14, 2021 securities purchase agreement. The company will not receive any proceeds from resale of these shares, but could receive up to $526,315 in gross proceeds if the warrants are exercised for cash, which it plans to use for general working capital, including litigation expenses. Separately, ParkerVision completed a primary offering of 16,481,579 shares of common stock to accredited investors for an aggregate purchase price of $3,461,132, conducted off its shelf registration statement without underwriters or fees.
ParkerVision, Inc. has filed a prospectus supplement covering the resale of up to 13,342,953 shares of common stock by selling stockholders. These shares include 7,962,722 shares issued under prior securities purchase agreements, 3,230,942 shares plus 1,619,289 warrant shares from March 29, 2021 agreements, and 530,000 shares issued as payment for services. The company will not receive proceeds from resales, but could receive up to $2,833,756 in gross proceeds if the related warrants are exercised for cash, which it expects to use for working capital and litigation expenses.
The supplement also attaches a Form 8-K describing a completed offering of 16,481,579 shares of common stock to accredited investors for an aggregate purchase price of $3,461,132, conducted off the company’s shelf registration statement. No underwriters, placement agents, brokers, or finders were used, and no commissions or fees were paid in connection with this primary offering.
ParkerVision, Inc. has filed a prospectus supplement tied to an existing resale registration that permits selling stockholders to resell up to 5,871,584 shares of its common stock issued under prior securities purchase agreements. The company will not receive any proceeds from these resale transactions. The supplement updates the prospectus by incorporating a new Form 8-K.
The attached Form 8-K reports that on November 24, 2025, ParkerVision completed an offering and sale of 16,481,579 shares of common stock to accredited investors for an aggregate purchase price of $3,461,132 under its shelf registration statement on Form S-3. The company conducted this primary offering without underwriters, placement agents, brokers, or finders and paid no commissions or fees.
ParkerVision, Inc. updated its April 2020 resale prospectus to cover up to 16,809,295 shares of common stock that may be sold from time to time by existing stockholders. These shares include stock already issued, shares issuable from convertible notes, and up to 5,200,000 shares underlying warrants held by Aspire Capital and Tailwinds. The company will not receive proceeds from stockholder resales, but could receive up to $3,900,000 if the Aspire and Tailwinds warrants are exercised for cash.
Separately, ParkerVision completed a registered offering of 16,481,579 shares of common stock to accredited investors for an aggregate purchase price of $3,461,132, using its shelf registration statement. The company did not use underwriters or pay commissions in this transaction, and disclosed the closing and related agreements through its Form 8-K and attached exhibits.
ParkerVision, Inc. has an effective prospectus supplement that permits the resale by existing stockholders of up to 18,014,164 shares of common stock. These consist of up to 5,457,583 shares issuable under Tranche 1 convertible notes at a fixed conversion price of $0.10 per share, up to 10,131,581 shares issuable under Tranche 2 convertible notes at a fixed conversion price of $0.08 per share, 625,000 shares issued for services under the Fisher Consulting Agreement, and up to 1,800,000 shares issuable upon exercise of the Park Consulting Warrant with a $0.10 exercise price.
The company will not receive proceeds from resale of these shares by selling stockholders, but could receive up to $180,000 in gross proceeds if the Park Consulting Warrant is exercised for cash. Separately, ParkerVision completed a registered offering of 16,481,579 shares of common stock to accredited investors for an aggregate purchase price of $3,461,132 under its Form S-3 shelf registration statement, with no commissions or fees paid.
ParkerVision, Inc. has filed a prospectus supplement covering the resale by existing stockholders of up to 17,189,660 shares of common stock. These shares include stock and warrants from a 2016 private placement, shares issued and issuable under a 2018 PIPE agreement with Aspire Capital, and shares issuable upon conversion of 2018 convertible notes. The company will not receive proceeds from stockholder resales, but could receive up to $700,000 from cash exercises of a 2016 warrant and up to $1,763,500 from sales of common stock or warrant exercises under the Aspire Capital agreement.
Separately, ParkerVision completed a registered direct offering of 16,481,579 shares of common stock to accredited investors for an aggregate purchase price of $3,461,132, using its Form S-3 shelf registration. No underwriters, placement agents, brokers, or finders were involved and no commissions or fees were paid.
ParkerVision, Inc. has filed a prospectus supplement that continues to permit the resale by selling stockholders of up to 12,800,000 shares of common stock previously registered under its shelf program. These shares consist of up to 7,800,000 shares issuable upon conversion of, or payment of interest on, convertible promissory notes and 5,000,000 shares issuable upon exercise of a five-year warrant.
The company will not receive proceeds from resale of these shares, but could receive up to $800,000 in gross proceeds if the warrant is exercised for cash, which it expects to use for patent enforcement, working capital, and general corporate purposes. The attached Form 8-K discloses that ParkerVision also completed a separate registered offering of 16,481,579 common shares to accredited investors for an aggregate purchase price of $3,461,132, with no commissions or fees paid.
ParkerVision, Inc. completed a primary offering of 16,481,579 shares of common stock to accredited investors at $0.21 per share, raising gross proceeds of $3,461,132. The shares were sold directly under subscription agreements without underwriters or placement agents, and the deal closed on November 24, 2025.
The company plans to use the cash for working capital, general corporate purposes, and litigation fees and expenses, which align with its IP-enforcement focused business model. On a pro forma basis as of September 30, 2025, cash would increase from $901,000 to $5,470,000, and total shareholders’ deficit would narrow from $(49.8) million to $(45.2) million, though the balance sheet remains highly leveraged.
The offering price creates meaningful dilution. Pro forma as adjusted net tangible book value moves from $(0.39) to $(0.32) per share, implying an immediate dilution of $0.53 per share to new investors buying at $0.21. The company continues to highlight substantial risks, including a limited OTCQB trading market, a need for additional capital, and going concern language in its audited financial statements.
ParkerVision, Inc. (PRKR) reported that on November 24, 2025 it completed an offering and sale of 16,481,579 shares of common stock to accredited investors for an aggregate purchase price of $3,461,132. The shares were issued under the company’s existing shelf registration statement on Form S-3 and a prospectus supplement containing the final terms of the offering.
The company conducted this transaction directly, engaging no underwriters, placement agents, brokers, or finders and paying no commissions or fees, so the full purchase price goes to ParkerVision. The company also disclosed that it issued a press release announcing the closing of the transaction, which is included as an exhibit.